Scarica l'app Stockscreener
66.39
0.30%
-0.20
Precedente Chiudi:
$66.59
Aprire:
$66.55
Volume 24 ore:
400.96K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.97B
Reddito:
$232.39M
Utile/perdita netta:
$-26.79M
Rapporto P/E:
-61.45
EPS:
-1.0804
Flusso di cassa netto:
$4.41M
1 W Prestazione:
+4.68%
1M Prestazione:
+27.43%
6M Prestazione:
+48.62%
1 anno Prestazione:
+154.47%
Intervallo 1D:
$63.50
$68.33
Intervallo di 1 settimana:
$60.94
$68.60
Portata 52W:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
66.39 | 1.97B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Is AnaptysBio (ANAB) outperforming other medical stocks this year? - MSN
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base? - simplywall.st
(ANAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB) - The Globe and Mail
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76 - Moomoo
AnaptysBio, Inc. Financial Disclosures & Filings - TradingView
CapForce IBD 50 ETF's AnaptysBio Inc(ANAB) Holding History - GuruFocus
Form 144 ANAPTYSBIO For: 30 June By Investing.com - Investing.com Nigeria
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
AnaptysBio Is Maintained at Buy by UBS - Moomoo
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Form 144 ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Form DEF 14A ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Enterprise value to revenue forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
ANAPTYSBIO, INC ($ANAB) CEO 2025 Pay Revealed - Quiver Quantitative
Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB) - Stock Titan
AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits - Stock Titan
Price to earnings forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Price to sales forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell 3000E Index - marketscreener.com
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index - marketscreener.com
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
ANAB News | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Form 144 ANAPTYSBIO For: 26 June By Investing.com - Investing.com Nigeria
ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May–June sales - Stock Titan
AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth? - Sahm
AnaptysBio, Inc. Actuals & Estimates (NASDAQ:ANAB) - TradingView
ANAB Forecast — Price Target — Prediction for 2027 - TradingView
AnaptysBio Inc. (ANAB) Surges 4.3% as Biotech Sentiment Improves — Key Levels to WatchQuality Factor - Město Břeclav
First Tracks Biotherapeutics (NASDAQ: TRAX) subleases 45,057 sq ft in San Diego - Stock Titan
ANAB Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Continues Pipeline InvestmentRevenue Guidance Update - dars.gov.et
AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
AnaptysBio Ord Shs (ANABV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eversept Partners LP Takes $5.86 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AnaptysBio Inc (ANAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. $ANAB Shares Purchased by 683 Capital Management LLC - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AnaptysBio Inc (ANAB) Institutional Confidence - TradingKey
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
850-share sale notice by insider at ANAB (NASDAQ: ANAB) via Form 144 - Stock Titan
AnaptysBio (ANAB) director acquires 6,030 shares via RSU vesting - Stock Titan
Director at AnaptysBio (NASDAQ: ANAB) receives 6,030 shares via RSUs - Stock Titan
Director John Orwin of ANAPTYSBIO (NASDAQ: ANAB) settles 6,030 RSUs into common stock - Stock Titan
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):